Trademark/Service Mark Application, Principal Register
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)
Trademark/Service Mark Application, Principal Register
The mark consists of standard characters, without claim to any particular font style, size, or color.
REGISTER
Principal
APPLICANT INFORMATION
*OWNER OF MARK
Auspex Pharmaceuticals, Inc.
INTERNAL ADDRESS
Suite 400
*STREET
3333 North Torrey Pines Court
*CITY
La Jolla
*STATE
(Required for U.S. applicants)
California
*COUNTRY
United States
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
92037
PHONE
215-293-6509
FAX
215-293-7200
EMAIL ADDRESS
XXXX
AUTHORIZED TO COMMUNICATE VIA EMAIL
Yes
LEGAL ENTITY INFORMATION
TYPE
corporation
STATE/COUNTRY OF INCORPORATION
Delaware
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS
005
*IDENTIFICATION
Pharmaceutical preparations for the treatment of central nervous system diseases namely, neurodegeneration, psychiatric conditions, pain and
movement disorders.
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)
Trademark/Service Mark Application, Principal Register
Serial Number:88420984
Filing Date:05/08/2019
To the Commissioner for Trademarks:
MARK: HYKENMO (Standard Characters, see mark)
The literal element of the mark consists of HYKENMO.
The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Auspex Pharmaceuticals, Inc., a corporation of Delaware, having an address of
Suite 400
3333 North Torrey Pines Court
La Jolla, California 92037
United States
215-293-6509(phone)
215-293-7200(fax)
XXXX
requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C.
Section 1051 et seq.), as amended, for the following:
International Class 005: Pharmaceutical preparations for the treatment of central nervous system diseases namely, neurodegeneration, psychiatric conditions,
pain and movement disorders.
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.
The applicant's current Correspondence Information:
Laurence Rickles
Teva Pharmaceuticals USA, Inc.
Trademarks Department
425 Privet Road
Horsham, Pennsylvania 19044
215-293-6509(phone)
215-293-7200(fax)
laurence.rickles@tevapharm.com;shelby.barilone@tevapharm.com (authorized) E-mail Authorization: I authorize the USPTO to send e-mail correspondence concerning the application to the applicant, the applicant's attorney, or the applicant's domestic representative at
the e-mail address provided in this application. I understand that a valid e-mail address must be maintained and that the applicant or the applicant's attorney must file the relevant subsequent
application-related submissions via the Trademark Electronic Application System (TEAS). Failure to do so will result in the loss of TEAS Reduced Fee status and a requirement to submit an additional
processing fee of $125 per international class of goods/services.
A fee payment in the amount of $275 has been submitted with the application, representing payment for 1 class(es).
Declaration
Declaration Signature
Signature: /Brian Shanahan/ Date: 05/08/2019
Signatory's Name: Brian Shanahan
Signatory's Position: Secretary
Payment Sale Number: 88420984
Payment Accounting Date: 05/09/2019
Serial Number: 88420984
Internet Transmission Date: Wed May 08 14:39:35 EDT 2019
TEAS Stamp: USPTO/BAS-XXX.XXX.XXX.XX-201905081439357
35955-88420984-620b67b3127a94d2744d60e61
87da7824c6c8677e44a99c4dff96b413cf56d3c3
-DA-814-20190508123730552777